At Kisbee Therapeutics, we are engineering recombinant lipoproteins to target the core biological systems underlying neurodegenerative diseases. Our work represents a novel approach to address the problem of lipid dysregulation observed across many CNS (central nervous system) diseases.
Genetically Validated Approach to Restore Lipid Homeostasis
A growing body of scientific evidence has linked dysfunctional lipid biology to the onset and severity of neurodegenerative disease.
Human genetics has shown that ineffective lipoprotein function as well as mutations in lipid transport genes are central drivers of neurodegeneration. Failure to properly regulate lipid transport between neurons, astrocytes, and microglia leads to excitotoxicity, impaired debris clearance, protein accumulation, inflammation, and reduced lysosomal function, all hallmarks of many neurodegenerative diseases.
By use of our highly optimized, engineered lipoproteins, also known as Kisbee Discs, we are able to intervene and restore lipid homeostasis – gathering and transporting lipids to where they are needed.
Kisbee is focused on advancing programs where we can use biomarkers to connect relevant biology in genetically defined patient populations to improve our ability to demonstrate efficacy and to further characterize the potential therapeutic benefit of our approach. Alzheimer’s disease, along with several other rare, chronic, and acute neurodegenerative conditions, are in focus for initial therapeutic development efforts.
At Kisbee, we have a shared mission with the patient communities we serve to develop new and impactful therapies. We know this mission is best achieved by working together and by having the patient’s perspective of the diseases we are researching.
To listen, really listen, to the patient communities we serve to understand unmet needs and your lived experience
To be transparent about our work
To actively partner with advocacy organizations globally throughout the drug development process
If you have questions or would like to connect with a member of our patient advocacy team, please contact us at patients@kisbeetx.com
Meet the experts behind our vision
Join us in creating a new class of therapeutics for neurodegenerative disease
Kisbee is developing lipid-based therapeutics for neurodegenerative diseases and CNS injuries by bringing together passionate scientists and drug developers. Our diverse experiences and perspectives enable us to support and challenge one another, fostering care, respect, and collaboration. New ideas and innovation fuel us. Science and data guide us. Novel challenges and opportunities bring out our best. We are passionate and driven, and we aspire to overcome obstacles with creativity and careful risk-taking, striving to make a difference for patients.
We show up, we speak with honesty and deliver what we promise. We are confident in one another’s capabilities, display integrity in all things, and assume best intent knowing that we each keep everyone’s best interests at heart
We embrace our different backgrounds, experiences, and viewpoints to strengthen our fabric and enhance our outcomes. Our interactions are driven by universal compassion, so we act with humility and a willingness to understand everyone’s perspective
We leverage our relentless passion for our patients, our business, and our science by creatively looking at things through a different lens, humbly considering alternatives, and remaining eager to learn
We share what we should, when we should. We trust each other to demonstrate sound discernment and to honor the best interests of the individuals when sharing
We exercise mature judgment so we’re entrusted to think, experiment, and discover for ourselves. We’re not afraid to take informed risks, embrace challenges, and push boundaries in order to grow Kisbee and support patients
We are actively hiring across a range of roles in R&D, HR, Finance, and Operations. To inquire about open roles, please email recruiting@kisbeetx.com
Albert Lo M.D., Ph.D., is a neurologist/neuroscientist with more than 23 years of clinical trial and research experience in neurodegeneration. He joined Kisbee in 2023 after spending eight years at Eli Lilly and Company, where his role was Vice President in Early Clinical Phase Neurodegeneration. At Lilly, Al was the global clinical leader for multiple Alzheimer’s disease clinical trial programs acting on protocol development, biomarkers translation plans, trial execution, and FDA interactions for anti-amyloid, anti-tau and anti-microglial molecules, such as zagotenemab, BACE inhibitor, and donanemab, which successfully met its primary endpoint for phase 2 and 3 trials. As the Head for the Neuroinflammatory and Neuromuscular Neurology at Lilly, Al led the neuroinflammatory portfolio and SARM1 inhibitor programs and spearheaded clinical development diligence for new and rare disease clinical indications. Most recently he led the emerging ALS clinical development pipeline and strategy across all modalities (large molecules, small molecules and genetic). For biotech acquisitions to further build the neurodegeneration pipeline, Al led the post-acquisition clinical development integration.
Prior to joining industry, Al spent 15 years in academic neurology with a focus on multiple sclerosis, stroke, and ALS, as well as research in Parkinson’s and traumatic brain injury. He was Associate Professor of Neurology, Engineering and Public Health at Brown University as well as Associate Director of the VARRD Center of Excellence for Neurorestoration and Neurotechnology at Providence VA Medical Center. During the seven years before Brown, Al was Assistant Professor of Neurology at Yale University, where he served as the study PI for the VA ROBOTICS phase 2/3 trial testing the MIT-Manus robot intervention for stroke neurorehabilitation. He also engaged in translational research, designing and conducting the initial animal neuroprotection studies examining sodium channel blockade in EAE which were then translated into clinical trial designs in MS. In 2007, Al became the founding Director for Neuroscience research at the Mandell MS Center at Mount Sinai Rehabilitation Hospital in Hartford, CT. He is a Past President of the American Society for Neurorehabilitation, an organization focused on neurorecovery through neuroscience discovery, and from 2019-2021 served as a member the National Advisory Board on Medical Rehabilitation Research, NIH/NCMRR. Al earned his MD/PhD (neuroscience) from Wake Forest University, is a graduate of UC Berkeley, and received his CPH from Harvard University. He completed his internship and neurology residency at Yale University.
